MIST vs. ANVS, PRPH, YS, BRNS, QTTB, CMRX, ETON, VACC, LFVN, and ONCY
Should you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Annovis Bio (ANVS), ProPhase Labs (PRPH), YS Biopharma (YS), Barinthus Biotherapeutics (BRNS), Q32 Bio (QTTB), Chimerix (CMRX), Eton Pharmaceuticals (ETON), Vaccitech (VACC), LifeVantage (LFVN), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical preparations" industry.
Annovis Bio (NYSE:ANVS) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, community ranking, profitability, analyst recommendations, earnings and dividends.
In the previous week, Annovis Bio had 9 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 14 mentions for Annovis Bio and 5 mentions for Milestone Pharmaceuticals. Annovis Bio's average media sentiment score of 0.97 beat Milestone Pharmaceuticals' score of 0.24 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.
Annovis Bio has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500.
Annovis Bio has higher earnings, but lower revenue than Milestone Pharmaceuticals. Annovis Bio is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 38.3% of Annovis Bio shares are held by company insiders. Comparatively, 10.4% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Milestone Pharmaceuticals received 56 more outperform votes than Annovis Bio when rated by MarketBeat users. However, 95.00% of users gave Annovis Bio an outperform vote while only 67.57% of users gave Milestone Pharmaceuticals an outperform vote.
Annovis Bio currently has a consensus target price of $23.50, indicating a potential upside of 182.79%. Milestone Pharmaceuticals has a consensus target price of $10.75, indicating a potential upside of 525.00%. Given Annovis Bio's higher probable upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Annovis Bio.
Annovis Bio's return on equity of -192.88% beat Milestone Pharmaceuticals' return on equity.
Summary
Milestone Pharmaceuticals beats Annovis Bio on 10 of the 14 factors compared between the two stocks.
Get Milestone Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Milestone Pharmaceuticals Competitors List
Related Companies and Tools
